CXCL1 and neoplasm: In many malignancies—particularly in carcinomas such as triple-negative breast cancer (TNBC), cervical cancer, platinum-resistant ovarian cancer, and advanced prostate cancer—iCAFs are a primary stromal source of CXCL1, thereby contributing to aggressive tumor biology, metastasis, and therapy resistance.